Navigation Links
RET rearrangement a new oncogene and potential target in lung cancer
Date:6/3/2013

In results presented at ASCO 2013, a University of Colorado Cancer Center study provides important details for a recently identified driver and target in lung adenocarcinoma: rearrangement of the gene RET. The finding is an important step along a trajectory like that which led to FDA approval of the drug crizotinib, which targets a somewhat similar rearrangement in the ALK gene. By comparison, the ALK rearrangement is present in 3-5 percent of lung cancers whereas the present study found RET rearrangements present in 8 of 51 (15.7 percent) of an enriched cohort of patient samples that did not show evidence of other oncogene alterations.

"This is an exciting finding. We know from the example of ALK-positive lung cancer that not only do rearrangements like this present druggable targets, but that at least in the case of ALK, the drugs matched to these mutations can create a stunning improvement in the lives of the targeted subset of lung cancer patients," says Marileila Garcia, PhD, investigator at the CU Cancer Center and professor at the CU School of Medicine.

The ALK mutation is targeted by crizotinib, frequently leading to improvements in patients with ALK+ lung cancer. Now it seems as if RET mutation could be targeted in a similar way, even perhaps with existing tyrosine-kinase inhibitors (TKIs) including vandetanib, sunitinib, sorafenib and ponatinib that are already used in the clinic for other tumor types.

"We're starting to pick apart these lung cancer subsets. And as we find drivers and then match them with drugs, we're increasingly able to offer treatments targeted to a specific cancer's genetic addiction. The cancer is ALK-positive? You target it with crizotinib. Now say the cancer is RET-positive? It looks promising that we may be able to target this mutation as well," says Robert C. Doebele, MD, PhD, investigator at the CU Cancer Center and assistant professor of medical oncology at the CU School of Medicine.

Specifically, the group developed a FISH assay to test for evidence of the RET rearrangement in lung adenocarcinoma patient samples. The RET gene inverts with nearby genes KIF5B, CCDC6 and NCOA4 to create a new fusion gene that contains components from both genes. This fusion gene then produces a protein that is always turned on and that drives the growth of these cancer cells. The investigators then confirmed the presence of these rearrangements by PCR-based methodology.

Preclinical evidence shows that the existing TKIs mentioned above inhibit the activity of this RET fusion protein, thus stopping the mutation's oncogenic ability and ultimately the growth of these cancer cells.

"This test is important," Garcia says. "One lesson of ALK-positive lung cancer is that not only do you need to know that a mutation causes cancer and that a drug can stop its action, but you have to know who has the rearrangement."

The group's test is an essential step in eventually prescribing targeted TKIs to only the patients most likely to benefit, namely those shown in the group's FISH assay to have the RET-fusion gene.


'/>"/>

Contact: Erika Matich
erika.matich@ucdenver.edu
303-524-2780
University of Colorado Denver
Source:Eurekalert

Related medicine news :

1. Tumors with ALK rearrangements can harbor more mutations
2. New oncogene identified for breast cancer
3. Dietary glucose affects the levels of a powerful oncogene in mice
4. Hepatitis B virus promotes oncogenesis through microRNA modulation
5. Preclinical study identifies master proto-oncogene that regulates ovarian cancer metastasis
6. Study identifies potential treatment for lethal childhood leukemia
7. McMaster researchers find potential for new uses of old drug
8. Army researcher develops potential vaccine carrier
9. UNC study shows potential to revive abandoned cancer drug by nanoparticle drug delivery
10. New study of NIH funding allocations suggests potential efficiency gains
11. A closer look at PARP-1 reveals potential new drug targets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... Aliso Viejo, California (PRWEB) , ... June 26, 2016 , ... ... for Final Cut Pro X. , "Film editors can give their videos a whole ... artistically," said Christina Austin - CEO of Pixel Film Studios. , ProSlice Levels ...
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery services, ... Mohs Surgery and to Dr. Russell Peckham for medical and surgical dermatology. , Dr. ... skin cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson ... Recently, he has implemented orthobiologic procedures as a method for treating his patients. ... the first doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is ... associated with chronic pain and the benefits of holistic treatments, Serenity Recovery Center ... suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder of ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Comfort Keepers® of ... Cancer Society and the Road To Recovery® program to drive cancer patients to and ... other adults to ensure the highest quality of life and ongoing independence. Getting ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... Mass. , June 24, 2016   Pulmatrix, ... pharmaceutical company developing innovative inhaled drugs, announced today that ... Russell Investments reconstituted its comprehensive set of ... "This is an important milestone for Pulmatrix," ... will increase shareholder awareness of our progress in developing ...
(Date:6/23/2016)... Research and Markets has announced the addition of the ... report to their offering. ... failure, it replaces the function of kidneys by removing the ... the treatment helps to keep the patient body,s electrolytes such ... Increasing number of ESRD patients & substantial healthcare expenditure on ...
(Date:6/23/2016)... , June 23, 2016 Roche (SIX: RO, ... clearance for its Elecsys BRAHMS PCT (procalcitonin) assay as ... or septic shock. With this clearance, Roche is the ... fully integrated solution for sepsis risk assessment and management. ... bacterial infection and PCT levels in blood can aid ...
Breaking Medicine Technology: